Related Experiment Video

Updated: Dec 17, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K

Tim-3 finds its place in the cancer immunotherapy landscape

Nandini Acharya1,2, Catherine Sabatos-Peyton3, Ana Carrizosa Anderson4,2

  • 1Department of Neurology, Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Journal for Immunotherapy of Cancer
|July 1, 2020
PubMed

Insights

Immune checkpoint blockade shows promise but has limitations. Targeting T-cell immunoglobulin and mucin domain 3 (Tim-3) alongside PD-1 may improve cancer treatment outcomes by enhancing antitumor T-cell responses.

Area of Science:

  • Immunology
  • Oncology

Background:

  • Immune checkpoint blockade has advanced cancer therapy for several malignancies.
  • However, significant challenges remain, including low response rates and refractoriness in certain cancers like microsatellite-stable colorectal cancer.

Purpose of the Study:

  • To review the biology of T-cell immunoglobulin and mucin domain 3 (Tim-3).
  • To explore Tim-3's role in the tumor microenvironment.
  • To discuss emerging clinical data on Tim-3's therapeutic potential in immuno-oncology.

Main Methods:

  • Review of existing literature on Tim-3 biology and function.
  • Analysis of preclinical models investigating Tim-3 blockade.
  • Examination of clinical trial data for Tim-3-based therapies.

Main Results:

  • Tim-3 is expressed on various immune cells and leukemic stem cells.
  • Co-blockade of Tim-3 and PD-1 demonstrates reduced tumor progression in preclinical settings.
  • Combined blockade enhances antitumor T-cell responses in cancer patients.

Conclusions:

  • Tim-3 represents a promising target for novel cancer immunotherapies.
  • Combination strategies involving Tim-3 blockade warrant further clinical investigation.
  • Targeting Tim-3 may overcome resistance to current immune checkpoint inhibitors.
Keywords:
clinical trials as topiccostimulatory and inhibitory T-cell receptorsimmunotherapytumor microenvironment

More Related Videos

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.2K
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.0K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.6K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
867
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K